Objectives: Both oral estrogen-based hormone-replacement therapy and contraceptives increase the risk of venous thromboembolism. Several circulating factors involved in coagulation/fibrinolysis are expressed mainly in the liver whilst some are expressed in extrahepatic tissues, including bone marrow. The aim of this study was to identify estrogen-responsive target genes involved in the pathogenesis of estrogen-induced venous thromboembolism. Methods: Ovariectomized mice were treated with 17b-estradiol and possible effects on the expression of genes related to coagulation/fibrinolysis were investigated using DNA microarray analyses. Results: None of the selected genes was regulated by 17b-estradiol in the liver. Interestingly, 17b-estradiol increased mRNA levels of coagulation factor V in the bone marrow/bone. Furthermore, this stimulatory effect of 17b-estradiol on coagulation factor V expression can be mediated via both estrogen receptor-a and -b. Conclusions: The expression of bone marrow-derived, but not liver-derived, coagulation factor V is increased by estrogen treatment in mice. The pathophysiological importance of this finding for estrogen-induced venous thromboembolism remains to be determined.
Introduction
Both estrogen-based hormone-replacement therapy (HRT) and oral contraceptives increase the risk of venous thromboembolism (VTE) (1 -4) . The increased risk is thought to be due to the estrogen component of these treatments but no clear molecular mechanism behind estrogen-induced VTE has yet been identified. Several factors involved in coagulation/fibrinolysis are generally regarded to be expressed mainly in the liver but some are also expressed in the bone marrow. Most previous studies on the effects of estrogen on hemostatic balance have focused on circulating liver-derived factors. It has been shown that oral contraceptives regulate the levels and activity of multiple circulating hemostatic factors. Activated protein C (APC) sensitivity as well as the plasma concentration and activity of antithrombin III, protein S and plasminogen activator inhibitor-I (3 -6) are reduced, while circulating levels of fibrinogen, prothrombin and coagulation factor VIII (4) have been reported to be increased by estrogen-based treatments. The aim of the present study was to identify estrogen-regulated target genes in liver and/or bone marrow of potential importance for the pathogenesis of estrogen-induced VTE. The mRNA levels of several hemostatic balance-related genes, i.e. the coagulation cascade, the anticoagulant system and the fibrinolytic system, were analysed in liver and bone marrow/bone, using the DNA microarray technique.
Materials and methods

Animals
Before ovariectomy, the mice were anesthezied with a mixture of ketamine hydrochloride (75 mg/kg; Ketalar; Pfizer AB, Täby, Sweden) and medetomidine (1 mg/kg, i.p.; Dormitor Vet.; Orion Pharma AB, Sollentuna, Sweden).
Short-term estrogen treatment Eight-week-old ovariectomized female C57Bl/6 mice were injected s.c. with 2.3 mg 17b-estradiol benzoate/mouse (Sigma, St Louis, MO, USA). The mice were killed 10, 24 and 48 h after the injection.
Long-term estrogen treatment Wild-type (WT) and estrogen receptor (ER)-inactivated mice were bred as previously described (7 -10) . The mice were ovariectomized at 2 months of age and then injected s.c. with 2.3 mg 17b-estradiol benzoate/mouse per day (Sigma) for 5 days/week for 3 weeks. Control mice received injections of vehicle (olive oil; Apoteksbolaget, Göteborg, Sweden). The Ethics Committee of Göteborg University approved this study.
DNA microarray analysis
RNA was isolated from the liver and bone marrow/bone (humerus) as described elsewhere (11, 12) . For microarray analysis of the long-term estrogen treatment experiment, the RNA samples were pooled into two pools per animal group. The RNA was reverse transcribed into cDNA, labeled and analysed by DNA microarray (MG-U74A Array; Affymetrix, Santa Clara, CA, USA).
Bioinformatics
Scanned output files were analysed using Affymetrix micro array suite version 5.0 software as described elsewhere (11) . For the long-term estrogen treatment experiment, comparisons were made between the two vehicle-treated and the two estrogen-treated GeneChips, generating a total of four comparisons. To be regarded as regulated by estrogen in WT mice, the gene had to be expressed at a detectable level (according to the Affymetrix algorithm) in all pools and at least two of the four comparisons had to be considered to be increased or decreased according to Affymetrix algorithms. The average fold increase or decrease should be at least 1.6-fold.
Real-time PCR analysis
The confirmatory real-time PCR analyses were run on samples from individual animals using the ABI Prism 7700 sequence detection system (PE Applied Biosystems, Stockholm, Sweden) as described elsewhere (n ¼ 4-8) (11) . The sequences of primers and FAM-labeled probes were: coagulation factor V (FV) forward primer: 5 0 -TCG-AGAACAAGATAAACCTAAAACCAT; reverse primer: 5 0 -AGCTGGCGCTTTCATCCA and probe: 5 0 -AGACAGG-AAGACCCCACATGATGAAGCAC; coagulation factor X (FX) forward primer: 5 0 -GGGCCGAGTCCACACTGAT; reverse primer: 5 0 -TCTCATGCGTGCGTCCAA and probe: 5 0 -CCGCTCACGATGCCCGTCTTCT. 18S rRNA was used as internal standard.
Statistical analysis
All real-time PCR data are expressed as means^S.E.M. Statistical significance was assessed by Student's t-test. A value of P , 0.05 was considered statistically significant.
Results
In order to identify estrogen-induced genes of potential interest for the hemostatic balance, 35 genes involved in coagulation/fibrinolysis and present on Affymetrix Chips MG-U74A were selected (Table 1) . These genes were, as expected, in general more highly expressed in the liver than in bone marrow/bone (13, 14) ( Table 1) . Coagulation factors V, VII, IX, X, XII and XIII were highly expressed in the liver while only FV and FX were expressed at detectable levels in the bone marrow/bone (Table 1 ). Expression analysis of FV mRNA levels in different tissues demonstrated that FV was highly expressed in liver and moderately expressed in bone marrow/bone while only low expression was found in muscle, kidney, fat and heart (Fig. 1A) .
Long-term 17b-estradiol treatment of ovariectomized mice did not regulate the expression of any of the selected genes in the liver. In contrast, and unexpectedly, FV and FX mRNA levels in bone marrow/bone were increased by long-term 17b-estradiol treatment (Table 1) . Real-time PCR analysis on individual mice (n ¼ 6-7) confirmed the microarray finding that 17b-estradiol strongly increased mRNA levels of both FV and FX in bone marrow/bone (Fig. 1B) .
The recent and interesting finding of a functional bone marrow-derived megakaryocytically produced pool of platelet FV in mice prompted us to further characterize the observed effects of 17b-estradiol on FV expression in bone marrow/bone (15) . In order to investigate whether FV is a primary or secondary target gene for the effect of 17b-estradiol in bone marrow/bone, a short-term 17b-estradiol experiment was performed. Ovariectomized mice were given a single injection of 17b-estradiol and FV mRNA levels were analyzed 10, 24 and 48 h after the injection using real-time PCR analyses on individual mice (n ¼ 6-7). FV mRNA levels were significantly increased 24 h after the 17b-estradiol treatment (Fig. 1C) .
To establish the ER specificity for the stimulatory effect of 17b-estradiol on FV mRNA levels, the effect of longterm 17b-estradiol treatment was compared in ovariectomized WT, ERa (Fig. 1D) . Thus, the stimulatory effect of 17b-estradiol on FV mRNA levels is dependent on ER expression but can be mediated both via ERa and via ERb.
Discussion
Both oral estrogen-based HRT and contraceptives increase the risk of VTE. Hitherto, the effect of oral contraceptives on the hemostatic balance has been focused on changes in plasma concentration and the changes in activity of different factors involved in the process.
The coagulation cascade factors are predominately regarded as being exclusively synthesized in the liver. However, significant expression of FV in bone marrow/ bone is supported by previous studies, demonstrating a clear expression in bone marrow-derived megakaryocytes (16, 17) . Furthermore, recent bone marrow transplant models as well as transgenic mouse studies have demonstrated that the murine platelet FV pool is derived entirely from synthesis within bone marrow-derived megakaryocytes, while the circulating plasma FV pool is liver derived (15, 18) .
In this study, we have shown that FV mRNA is increased in the bone marrow/bone by long-as well as short-term 17b-estradiol treatment in female ovariectomized mice. The presence of both a short-term and long-term stimulatory effect of 17b-estradiol indicates that 17b-estradiol directly regulates FV mRNA levels. A direct regulatory effect of estrogen on FV gene expression is supported by the presence of halfpalindromic estrogen response element motifs in the promoter of this gene (19) . No effect of estrogen on the circulating FV levels has been reported, which can probably be explained by the fact that circulating FV is mainly liver derived (20, 21) , together with the present finding that 17b-estradiol does not regulate liver production of FV. Nevertheless, the present finding of estradiol-induced FV expression in bone marrow/bone might be of importance, as this bone marrow-derived pool of FV has recently been shown to have a functional role in the coagulation cascade (15) . FV has a central role in both the procoagulant and the anticoagulant pathways. In addition, APC resistance, the most common inherited coagulation deficiency, is in most cases caused by a single point (R506Q) mutation in the FV DNA microarray analyses were performed on mRNA prepared from liver and bone marrow/bone from ovariectomized mice treated with vehicle or 17b-estradiol according to the Materials and methods. Exp., the average mRNA expression (signal according to Affymetrix); -, not detectable; *0-500; **501 -2000; ***2001 -8000; **** . 8000. Estrogen-induced regulation (Reg.) of mRNA levels of genes expressed at detectable levels is indicated by N, no change and I, increased by estrogen according to the criteria given in the text.
gene (22) . One may therefore speculate that estrogeninduced high levels of bone marrow-derived FV might be involved in the pathogenesis of VTE.
In conclusion, mRNA levels of FV are strongly increased by 17b-estradiol in bone marrow/bone, but not in the liver. This effect of 17b-estradiol is mediated both via ERa and ERb and one may speculate that FV regulation might be involved in the pathogenesis of estrogen-induced VTE. 
